Eberprot-P

The newest drug, Eberprot-P, developed by Cuban specialists with the help of modern biotechnology, is successfully used as a therapy for ulcerative skin diseases in patients with diabetes mellitus. A few years ago, diabetic involvement of the lower extremities often led to forced amputation.

This drug has been tested and refined for more than two decades, and only now is represented in the world of medicine as a unique and effective in its way.

The drug EberPort-P is released in pharmacies if a prescription is available.

[1]

Indications Eberprot-P

Eberprot-P is used for medicinal purposes in diabetic foot syndrome in patients with trophic and neuropathic ulcers of grade 3 and 4 (according to Wagner's classification), measuring more than 1 square centimeter, with the threat of limb amputation. Especially require the use of Eberprot-P long-term non-healing ulcers, which are characterized by deep tissue damage.

[2],

Release form

Powdered substance for making a solution for injection in vials, 1 or 6 pieces in a package.

Each vial contains a recombinant epidermal factor of human growth in an amount of 75 μg, as well as some auxiliary substances.

[3], [4]

Pharmacodynamics

The active substance Eberprot-P is a protein that can stimulate cell growth and differentiate epithelial cover with EGF. The protein consists of 53 amino acid residues and three intramolecular disulfide bonds.

The drug activates the migratory and proliferative properties of fibroblasts, keratinocytes and other cells that promote the healing of ulcers, the normal growth of the epithelium and the renewal of tissues.

The drug is of great importance for the regulation of metabolic processes and recovery in the body. Connecting with receptors on the surfaces of cell membranes, Eberprot-P activates anti-inflammatory processes, as well as differentiation of regenerating cells, so that the wound heals quickly and qualitatively.

In addition, the drug controls the growth of epithelial, endothelial cells and fibroblasts, accelerates proliferative processes in tissues, stabilizes the motor response of cells as a result of the action of stimuli. 

[5]

Pharmacokinetics

There are no reliable scientific data on the chemical and biological processes that occur with the Eberprot-P preparation in the body. The processes of biochemical transformation of active substance molecules (suction rate, degree of distribution, metabolism and excretion of Eberprot-P) have not been sufficiently studied.

Dosing and administration

Before using Eberprot-P, possible infections should be treated in areas with ulcers.

If the quality of the wound is questionable, a tissue biopsy should be performed.

The drug is used against a background of complex therapy of the disease. The standard dosage is 75 μg, which is diluted with 5 ml of water for injection. It is used for the cutting of wounds or near-marginal area, usually every other day. Treatment continues until the epithelium proliferates, or until the wound is ready for a skin transplant operation.

When rubbing the wound, the needles should be changed when changing the Eberprot-P insertion sites in order to avoid the possible spread of the infection.

If a three-week period of continuous treatment does not improve the dynamics of the granulation process, the doctor should review the therapeutic measures and find a cause that may interfere with the healing of the wound.

A medicinal substance from one vial can be used only for the same patient.

[8]

Use Eberprot-P during pregnancy

Data on the effect of Eberprot-P on the course of pregnancy and the developing embryo are not currently available. The decision on the possibility of using Eberprot-P in the period of bearing the child should be taken by the doctor, after assessing the picture of the disease and the possible risk for the future baby. 

Contraindications

Contraindications for the appointment of Eberprot-P are:

• allergic sensitivity of the organism to any of the constituents of the medicinal product;
• presence of benign and malignant tumors in the treated area of skin;
• signs of diabetic coma and ketoacidosis, cardiopathy in the stage of decompensation;
• pregnancy and lactation;
• newborn children.

[6]

Side effects Eberprot-P

The main side effects when using Eberprot-P are:

• soreness and sensitivity disorders at the injection site;
• feverish conditions;
• feeling of trembling in the limbs;
• development of local infection;
• feeling of heat.

[7],

Overdose

There were no cases of drug overdose. There is no special antidote medication.

With possible suspicions of an overdose, the drug is symptomatic.

Interactions with other drugs

Studies that determine the compatibility and interaction of Eberproth-P with other medicines have not been carried out. Therefore, it is recommended to avoid the use of topical products for external use during drug treatment.

[9], [10]

Storage conditions

The drug should be stored in the original packaging in a refrigerator; not subject to freezing! It is necessary to protect the drug from admission of children.

[11]

Shelf life

Shelf life Eberprot-P - 2 years. The diluted product is to be used immediately. At the end of treatment, the unused remedy should be discarded.

[12], [13]